Drug Profile


Alternative Names: FIAC; FOAC

Latest Information Update: 10 Jan 2001

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Oclassen Pharmaceuticals
  • Class Antivirals; Arabinonucleosides; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cytomegalovirus infections; Herpes simplex virus infections

Most Recent Events

  • 10 Jan 2001 Discontinued-II for Cytomegalovirus infections in USA (PO)
  • 10 Jan 2001 Discontinued-II for Herpes simplex virus infections in USA (PO)
  • 29 Sep 1998 No-Development-Reported for Herpes simplex virus infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top